| Trial ID: | L1957 |
| Source ID: | NCT00123227
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Rosiglitazone Plaque Study
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Vascular Diseases|Hypertension
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR) | Secondary: Change in plaque lipid content|Change in plaque fibrous cap thickness|Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation
|
| Sponsor/Collaborators: |
Sponsor: Royal Brompton & Harefield NHS Foundation Trust | Collaborators: GlaxoSmithKline|CORDA, The Heart Charity
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-10
|
| Completion Date: |
2005-05
|
| Results First Posted: |
|
| Last Update Posted: |
2005-08-01
|
| Locations: |
Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, SW3 6NP, United Kingdom|St Mary's NHS Trust, London, W2 1NY, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00123227
|
